Stock Events

Stock Events

Capricor Therapeutics 

0
91
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q1 2026
Next
-0.52
-0.49
-0.46
-0.43
Expected EPS
-0.5168518
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4LN1.STU. It's not an investment recommendation.
NVIDIA
24
NVDA
Alphabet
19
GOOGL
Tesla
18
TSLA
Bitcoin
18
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, directly competing with Capricor's focus on cardioskeletal diseases and Duchenne muscular dystrophy.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for genetic diseases, competing in the same space as Capricor.
PTC Therapeutics
PTCT
Mkt Cap7.09B
PTC Therapeutics focuses on the development of orally administered small molecule drugs that regulate gene expression, including treatments for muscular dystrophy, overlapping with Capricor's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap1.07B
Solid Biosciences is dedicated to solving Duchenne muscular dystrophy (DMD) and other neuromuscular diseases, directly competing with Capricor's DMD programs.
Forte Biosciences
FBRX
Mkt Cap428.42M
Forte Biosciences specializes in developing therapies for dermatological diseases but also explores treatments in other areas that could potentially overlap with Capricor's research in regenerative medicine.
Pfizer
PFE
Mkt Cap138.61B
Pfizer, a large pharmaceutical company, has a broad range of products including in areas that compete with Capricor's niche, such as cardiovascular and rare diseases treatments.
Moderna
MRNA
Mkt Cap31.65B
Moderna, known for its mRNA technology, is exploring treatments in areas that could compete with Capricor, especially in regenerative medicine and rare diseases.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline has a diverse portfolio that includes vaccines and treatments for a variety of diseases, some of which may compete with Capricor's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap223.19B
Novo Nordisk focuses on diabetes care but also has interests in hemophilia and growth disorders, potentially competing with Capricor's cardioskeletal and rare disease treatments.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, areas that overlap with Capricor's research interests in genetic and rare diseases.

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Show more...
CEO
ISIN
US14070B1017

Listings

STU
DE
4LN2.STU
F
DE
4LN2.F
STU
DE
4LN1.STU
XNAS
US
CAPR

0 Comments

Share your thoughts

FAQ

What is Capricor Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Capricor Therapeutics stocks are traded under the ticker 4LN1.STU.
When is the next Capricor Therapeutics earnings date?▼
Capricor Therapeutics is going to release the next earnings report on August 12, 2026.
What were Capricor Therapeutics earnings last quarter?▼
4LN1.STU earnings for the last quarter are -0.5 EUR per share, whereas the estimation was -0.43 EUR resulting in a -16.26% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Capricor Therapeutics located?▼
Capricor Therapeutics operates in the Other sector.
When did Capricor Therapeutics complete a stock split?▼
Capricor Therapeutics has not had any recent stock splits.